Enhanced antitumour efficiency of R(8)GD-modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumour metastasis
Enhanced antitumour efficiency of R(8)GD-modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumour metastasis
复制标题
R(8)GD修饰表柔比星联合汉防己碱脂质体通过抑制肿瘤转移提高胃癌治疗效果
DOI：
10.1080/08982104.2020.1748647
复制
发表时间：
2021
影响因子：
4.4
通讯作者：
Wang Xiao-Bo
中科院分区：
文献类型：
--
作者：
Li Xue-Tao;Jing Ming;Cai Fu-Yi;Yao Xue-Min;Kong Liang;Wang Xiao-Bo
肿瘤转移是导致癌症治疗失败和死亡的主要原因之一，而胃癌患者的化疗效果往往因肿瘤细胞转移、靶向性差、不良反应严重而不理想。本研究制备了一种R8 GD修饰的表阿霉素-粉防己碱脂质体，通过杀伤肿瘤细胞、破坏肿瘤转移和抑制肿瘤细胞能量供应来提高抗肿瘤效率。为研究靶向脂质体的抗肿瘤作用，通过体外形态学观察、细胞内摄取、细胞毒作用、对肿瘤转移和能量供应的抑制作用，以及荷瘤小鼠体内抗肿瘤作用的研究，结果表明，具有理想理化性质的R8 GD修饰的表阿霉素-汉防己甲素脂质体对肿瘤细胞的杀伤率最高，体内实验结果表明，R8 GD修饰的表阿霉素加汉防己甲素脂质体能增强肿瘤部位的蓄积，显示出明显的抗肿瘤作用。因此，R8 GD修饰的表阿霉素-粉防己碱脂质体可作为一种潜在的治疗胃癌的药物。
Tumour metastasis is a major cause of cancer treatment failure and death, and chemotherapy efficiency for gastric cancer patients is usually unsatisfactory due to tumour cell metastasis, poor targeting and serious adverse reactions. In this study, a kind of R8GD-modified epirubicin plus tetrandrine liposomes was prepared to enhance the antitumor efficiency via killing tumour cells, destroying tumour metastasis and inhibiting energy supply for tumour cells. In order to investigate the antitumour efficiency of the targeting liposomes, morphology observation, intracellular uptake, cytotoxic effects, and inhibition on tumour metastasis and energy supply were carried outin vitro, and tumour-bearing mice models were established to investigate the antitumour efficiencyin vivo.In vitroresults showed that R8GD-modified epirubicin plus tetrandrine liposomes with ideal physicochemical properties could kill the most tumour cells, inhibit tumour metastasis and cut-off energy supply for tumour cells.In vivoresults exhibited that R8GD-modified epirubicin plus tetrandrine liposomes could enhance the accumulation in tumour site and display an obvious antitumor efficiency. Therefore, R8GD-modified epirubicin plus tetrandrine liposomes could be used as a potential therapy for treatment of gastric cancer.